Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with fish and assessment of interobserver reproducibility

Bettina G. Papouchado, Jonathan Myles, Ricardo V. Lloyd, Mark Stoler, Andre M. Oliveira, Erinn Downs-Kelly, Adrienne Morey, Michael Bilous, Raymond B Nagle, Nichole Prescott, Lin Wang, Lidija Dragovich, Abigail McElhinny, Carole Ferrell Garcia, Jim Ranger-Moore, Heather Free, William Powell, Margaret Loftus, James Pettay, Fabien GaireChristopher Roberts, Manfred Dietel, Patrick Roche, Thomas Grogan, Raymond Tubbs

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best method for assessing HER2 status. Disadvantages of fluorescence in situ hybridization (FISH) testing include longer time required for staining and scoring slides, requirements for specialized training and fluorescence microscopy, and loss of the signal due to quenching of the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid fully automated assay providing permanently stained slides that are interpreted by conventional bright field microscopy which enables pathologists to evaluate slides within the context of tissue morphology. This study evaluates the concordance between SISH and FISH assays in determining the status of HER2 gene amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, we assessed in detail the variables contributing to interobserver interpretive reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the ratio of HER2 to CHR17 signals using the conventional historical interpretation scale and also by the American Society of Clinical Oncology/College of American Pathologists reporting scheme. For SISH status determined by consensus among 10 pathologists, overall concordance between SISH and FISH was identified in 288 of 298 cases (96.6%) using the conventional Food and Drug Administration approved criteria. Overall agreement was observed in 282 of 285 cases (98.9%) using the American Society of Clinical Oncology/College of American Pathologists result reporting scheme (with equivocal cases removed). In conclusion, SISH represents a novel approach for the determination of HER2 status in breast cancer. The overall concordance between SISH and FISH is excellent, and the interpretation of SISH results by pathologists is most reproducible using the HER2/CHR17 ratio.

Original languageEnglish (US)
Pages (from-to)767-776
Number of pages10
JournalAmerican Journal of Surgical Pathology
Volume34
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

erbB-2 Genes
Silver
In Situ Hybridization
Fishes
Breast Neoplasms
Fluorescence In Situ Hybridization
Gene Amplification
United States Food and Drug Administration
Fluorescent Dyes
Fluorescence Microscopy
Pathologists
Microscopy
Staining and Labeling

Keywords

  • CISH
  • Fluorescence in situ hybridization
  • HER2
  • Silver in situ hybridization
  • SISH

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma : Comparison with fish and assessment of interobserver reproducibility. / Papouchado, Bettina G.; Myles, Jonathan; Lloyd, Ricardo V.; Stoler, Mark; Oliveira, Andre M.; Downs-Kelly, Erinn; Morey, Adrienne; Bilous, Michael; Nagle, Raymond B; Prescott, Nichole; Wang, Lin; Dragovich, Lidija; McElhinny, Abigail; Garcia, Carole Ferrell; Ranger-Moore, Jim; Free, Heather; Powell, William; Loftus, Margaret; Pettay, James; Gaire, Fabien; Roberts, Christopher; Dietel, Manfred; Roche, Patrick; Grogan, Thomas; Tubbs, Raymond.

In: American Journal of Surgical Pathology, Vol. 34, No. 6, 06.2010, p. 767-776.

Research output: Contribution to journalArticle

Papouchado, BG, Myles, J, Lloyd, RV, Stoler, M, Oliveira, AM, Downs-Kelly, E, Morey, A, Bilous, M, Nagle, RB, Prescott, N, Wang, L, Dragovich, L, McElhinny, A, Garcia, CF, Ranger-Moore, J, Free, H, Powell, W, Loftus, M, Pettay, J, Gaire, F, Roberts, C, Dietel, M, Roche, P, Grogan, T & Tubbs, R 2010, 'Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with fish and assessment of interobserver reproducibility', American Journal of Surgical Pathology, vol. 34, no. 6, pp. 767-776. https://doi.org/10.1097/PAS.0b013e3181d96231
Papouchado, Bettina G. ; Myles, Jonathan ; Lloyd, Ricardo V. ; Stoler, Mark ; Oliveira, Andre M. ; Downs-Kelly, Erinn ; Morey, Adrienne ; Bilous, Michael ; Nagle, Raymond B ; Prescott, Nichole ; Wang, Lin ; Dragovich, Lidija ; McElhinny, Abigail ; Garcia, Carole Ferrell ; Ranger-Moore, Jim ; Free, Heather ; Powell, William ; Loftus, Margaret ; Pettay, James ; Gaire, Fabien ; Roberts, Christopher ; Dietel, Manfred ; Roche, Patrick ; Grogan, Thomas ; Tubbs, Raymond. / Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma : Comparison with fish and assessment of interobserver reproducibility. In: American Journal of Surgical Pathology. 2010 ; Vol. 34, No. 6. pp. 767-776.
@article{a122d78d05464eeaa0e084bd8ab32714,
title = "Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with fish and assessment of interobserver reproducibility",
abstract = "The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best method for assessing HER2 status. Disadvantages of fluorescence in situ hybridization (FISH) testing include longer time required for staining and scoring slides, requirements for specialized training and fluorescence microscopy, and loss of the signal due to quenching of the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid fully automated assay providing permanently stained slides that are interpreted by conventional bright field microscopy which enables pathologists to evaluate slides within the context of tissue morphology. This study evaluates the concordance between SISH and FISH assays in determining the status of HER2 gene amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, we assessed in detail the variables contributing to interobserver interpretive reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the ratio of HER2 to CHR17 signals using the conventional historical interpretation scale and also by the American Society of Clinical Oncology/College of American Pathologists reporting scheme. For SISH status determined by consensus among 10 pathologists, overall concordance between SISH and FISH was identified in 288 of 298 cases (96.6{\%}) using the conventional Food and Drug Administration approved criteria. Overall agreement was observed in 282 of 285 cases (98.9{\%}) using the American Society of Clinical Oncology/College of American Pathologists result reporting scheme (with equivocal cases removed). In conclusion, SISH represents a novel approach for the determination of HER2 status in breast cancer. The overall concordance between SISH and FISH is excellent, and the interpretation of SISH results by pathologists is most reproducible using the HER2/CHR17 ratio.",
keywords = "CISH, Fluorescence in situ hybridization, HER2, Silver in situ hybridization, SISH",
author = "Papouchado, {Bettina G.} and Jonathan Myles and Lloyd, {Ricardo V.} and Mark Stoler and Oliveira, {Andre M.} and Erinn Downs-Kelly and Adrienne Morey and Michael Bilous and Nagle, {Raymond B} and Nichole Prescott and Lin Wang and Lidija Dragovich and Abigail McElhinny and Garcia, {Carole Ferrell} and Jim Ranger-Moore and Heather Free and William Powell and Margaret Loftus and James Pettay and Fabien Gaire and Christopher Roberts and Manfred Dietel and Patrick Roche and Thomas Grogan and Raymond Tubbs",
year = "2010",
month = "6",
doi = "10.1097/PAS.0b013e3181d96231",
language = "English (US)",
volume = "34",
pages = "767--776",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma

T2 - Comparison with fish and assessment of interobserver reproducibility

AU - Papouchado, Bettina G.

AU - Myles, Jonathan

AU - Lloyd, Ricardo V.

AU - Stoler, Mark

AU - Oliveira, Andre M.

AU - Downs-Kelly, Erinn

AU - Morey, Adrienne

AU - Bilous, Michael

AU - Nagle, Raymond B

AU - Prescott, Nichole

AU - Wang, Lin

AU - Dragovich, Lidija

AU - McElhinny, Abigail

AU - Garcia, Carole Ferrell

AU - Ranger-Moore, Jim

AU - Free, Heather

AU - Powell, William

AU - Loftus, Margaret

AU - Pettay, James

AU - Gaire, Fabien

AU - Roberts, Christopher

AU - Dietel, Manfred

AU - Roche, Patrick

AU - Grogan, Thomas

AU - Tubbs, Raymond

PY - 2010/6

Y1 - 2010/6

N2 - The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best method for assessing HER2 status. Disadvantages of fluorescence in situ hybridization (FISH) testing include longer time required for staining and scoring slides, requirements for specialized training and fluorescence microscopy, and loss of the signal due to quenching of the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid fully automated assay providing permanently stained slides that are interpreted by conventional bright field microscopy which enables pathologists to evaluate slides within the context of tissue morphology. This study evaluates the concordance between SISH and FISH assays in determining the status of HER2 gene amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, we assessed in detail the variables contributing to interobserver interpretive reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the ratio of HER2 to CHR17 signals using the conventional historical interpretation scale and also by the American Society of Clinical Oncology/College of American Pathologists reporting scheme. For SISH status determined by consensus among 10 pathologists, overall concordance between SISH and FISH was identified in 288 of 298 cases (96.6%) using the conventional Food and Drug Administration approved criteria. Overall agreement was observed in 282 of 285 cases (98.9%) using the American Society of Clinical Oncology/College of American Pathologists result reporting scheme (with equivocal cases removed). In conclusion, SISH represents a novel approach for the determination of HER2 status in breast cancer. The overall concordance between SISH and FISH is excellent, and the interpretation of SISH results by pathologists is most reproducible using the HER2/CHR17 ratio.

AB - The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best method for assessing HER2 status. Disadvantages of fluorescence in situ hybridization (FISH) testing include longer time required for staining and scoring slides, requirements for specialized training and fluorescence microscopy, and loss of the signal due to quenching of the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid fully automated assay providing permanently stained slides that are interpreted by conventional bright field microscopy which enables pathologists to evaluate slides within the context of tissue morphology. This study evaluates the concordance between SISH and FISH assays in determining the status of HER2 gene amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, we assessed in detail the variables contributing to interobserver interpretive reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the ratio of HER2 to CHR17 signals using the conventional historical interpretation scale and also by the American Society of Clinical Oncology/College of American Pathologists reporting scheme. For SISH status determined by consensus among 10 pathologists, overall concordance between SISH and FISH was identified in 288 of 298 cases (96.6%) using the conventional Food and Drug Administration approved criteria. Overall agreement was observed in 282 of 285 cases (98.9%) using the American Society of Clinical Oncology/College of American Pathologists result reporting scheme (with equivocal cases removed). In conclusion, SISH represents a novel approach for the determination of HER2 status in breast cancer. The overall concordance between SISH and FISH is excellent, and the interpretation of SISH results by pathologists is most reproducible using the HER2/CHR17 ratio.

KW - CISH

KW - Fluorescence in situ hybridization

KW - HER2

KW - Silver in situ hybridization

KW - SISH

UR - http://www.scopus.com/inward/record.url?scp=77953044525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953044525&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3181d96231

DO - 10.1097/PAS.0b013e3181d96231

M3 - Article

C2 - 20421783

AN - SCOPUS:77953044525

VL - 34

SP - 767

EP - 776

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -